+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma



Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma



Annals of Oncology 2019



The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility and safety of cetuximab-based IC (paclitaxel/carboplatin/cetuximab-PCC, and docetaxel/cisplatin/5-fluorouracil/cetuximab-C-TPF) followed by local therapy in LAHNSCC. The primary endpoint of this phase II clinical trial with randomization to PCC and C-TPF followed by combined local therapy in patients with LAHNSCC stratified by human papillomavirus (HPV) status and T-stage was two-year progression free survival (PFS) compared to historical control. Eligible patients were ≥18 years with squamous cell carcinoma of the oropharynx, oral cavity, nasopharynx, hypopharynx or larynx with measurable stage IV (T0-4N2b-2c/3M0) and known HPV by p16 status. Stratification was by HPV and T-stage into one of two risk groups: (1) low-risk: HPV-positive and T0-3 or HPV-negative and T0-2; (2) intermediate/high-risk: HPV-positive and T4 or HPV-negative and T3-4. Patient reported outcomes were performed. 136 patients were randomized in the study, 68 to each arm. With a median follow up of 3.2 years, the two-year PFS in the PCC arm was 89% in the overall, 96% in the low-risk and 67% in the intermediate/high-risk groups; in the C-TPF arm two-year PFS was 88% in the overall, 88% in the low-risk and 89% in the intermediate/high-risk groups. The observed two-year PFS of PCC in the low-risk group and of C-TPF in the intermediate/high-risk group showed a 20% improvement compared to the historical control derived from RTOG-0129, therefore reaching the primary endpoint of the trial.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066048559

Download citation: RISBibTeXText

PMID: 30596812

DOI: 10.1093/annonc/mdy549


Related references

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology 3: 5, 2013

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. European Journal of Cancer 49(2): 352-359, 2013

A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer 119(4): 766-773, 2013

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). Frontiers in Oncology 9: 6, 2019

Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?. Journal of Cancer Research and Therapeutics 13(3): 510-513, 2018

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. Experimental and Therapeutic Medicine 5(4): 1247-1253, 2013

Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Journal of Clinical Oncology 28(36): 5294-5300, 2011

Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. Cancer ChemoTherapy and Pharmacology 77(6): 1315-1319, 2017

Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. International Journal of Radiation Oncology, Biology, Physics 82(5): 1845-1850, 2012

Carboplatin Versus Cetuximab Chemoradiation in Cisplatin Ineligible Patients with Locally Advanced p16 Negative Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology*biology*physics 99(2): E322-E323, 2017

Improved Outcomes With Carboplatin-Paclitaxel Compared to Docetaxel-Cisplatin-5-Fluorouracil Induction Chemotherapy in Locally-Advanced Squamous Cell Cancer of the Head and Neck. International Journal of Radiation Oncology*biology*physics 87(2): S474-S475, 2013

A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. Cancer Investigation 35(1): 23-31, 2016

Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. International Journal of Radiation Oncology, Biology, Physics 98(4): 948-954, 2017

A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN). American Journal of Clinical Oncology 39(5): 522-527, 2017

Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). Journal of Clinical Oncology 24(18_Suppl): 5520-5520, 2016